
    
      Upon determination of eligibility, patients will receive:

        -  Cyclophosphamide + Mitoxantrone + Vincristine + Prednisone + Rituximab

      Patients that are not considered candidates for anthracycline therapy will not receive
      mitoxantrone. Patients with objective response (partial or complete response) or stable
      disease will receive Rituximab maintenance therapy.
    
  